Comprehensive Psychiatry
Volume 41, Issue 2, Supplement 1 , Pages 66-75 , March 2000

Prediction of deterioration in mild cognitive disorder in old age—neuropsychological and neurochemical parameters of dementia diseases

  • Friedel M. Reischies

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Friedel M. Reischies, M.D., Ph.D., Department of Psychiatry, Freie Universität Berlin, Eschenallee 3, 14050 Berlin.
    • From the Department of Psychiatry, Free University of Berlin, Berlin, Germany.
    • ,
  • Rainer Hellweg

      Affiliations

    • From the Department of Psychiatry, Free University of Berlin, Berlin, Germany.

References 

  1. Wernicke TF, Reischies FM. Prevalence of dementia in old age-clinical diagnoses in subjects aged 95 years and over. Neurology. 1994;44:250–253
  2. Berg L, Danziger WL, Storandt M, Cohen LA, Gado M, Hughes CP, et al. Predictive features in mild senile dementia of the Alzheimer type. Neurology. 1984;34:563–569
  3. Paykel ES, Brayne C, Huppert FA, Gill C, Barkley C, Gehlhaar E, et al. Incidence of dementia in a population older than 75 years in the United Kingdom. Arch Gen Psychiatry. 1994;51:325–332
  4. Korten AE, Henderson AS, Christensen H, Jorm AF, Rodgers B, Jacomb P, et al. A prospective study of cognitive function in the elderly. Psychol Med. 1997;27:919–930
  5. Schmand B, Lindeboom J, Launer L, Dinkgreve M, Hooijer C, Jonker C. What is a significant score change on the Mini-Mental State Examination?. Int J Geriatr Psychiatry. 1995;10:411–414
  6. Christensen H, Henderson AS, Jorm AF, Mackinnon AJ, Scott R, Korten AE. ICD-mild cognitive disorder: epidemiological evidence on its validity. Psychol Med. 1995;25:105–120
  7. Auflage Reischies FM. Leichte Kognitive Störung. In: Helmchen H, Henn F, Laüter H, Sartorius N editor. Psychiatrie der Gegenwart. vol 4:Berlin, Germany: Springer; 1999;p. 225–246
  8. Reischies FM. Age related cognitive decline and the dementia threshold. In: Lomranz J editors. Handbook of Aging and Mental Health. An Integrative Approach. New York, NY: Plenum; 1998;p. 435–448
  9. Helmchen H, Reischies FM. Normales and pathologisches kognitives Altern. Nervenarzt. 1998;69:369–378
  10. Snowdon DA, Kemper SJ, Mortimer JA, Greiner LH, Wekstein DR, Markesbery WR. Linguistic ability in early life and cognitive function and Alzheimer's disease in late life. Findings from the Nun Study. JAMA. 1996;275:528–532
  11. Aylward E, Walker E, Bettes B. Intelligence in schizophrenia: meta-analysis of the research. Schizophr Bull. 1984;10:430–459
  12. Reischies FM. Heterogeneity of the time course of cognitive performance of depressed patients. In: Bergener M, Belmaker RH, Tropper MS editor. Psychopharmacotherapy for the Elderly-Research and Clinical Implications. New York, NY: Springer; 1993;p. 318–327
  13. Ritchie K, Leibovici D, Ledesert B, Touchon J. A typology of sub-clinical senescent cognitive disorder. Br J Psychiatry. 1996;168:470–476
  14. Lindenberger U, Reischies FM. Limits and potentials of intellectual functioning in old age. In: Baltes PB, Mayer KU editor. The Berlin Aging Study: Aging From 70 to 100. New York, NY: Cambridge University Press; 1998;p. 329–359
  15. Reischies FM, Felsenberg D, Geßner R, Kage A, Rossius W, Schlattmann P. Age and dementia effect on neuropsychological performance in very old age-influence of risk factors for dementia. J Neural Transm Suppl. 1998;53:69–76
  16. Geßiner R, Reischies FM, Kage A, Geiselmann B, Borchelt M, Steinhagen-Thiessen E, et al. In an epidemiological sample the apolipoprotein E4 allele is associated to dementia and loss of memory only in the very old. Neurosci Lett. 1997;222:29–32
  17. Reischies FM, Geiselmann B. Age related cognitive decline and vision impairment affecting the detection of dementia syndrome in old age. Br J Psychiatry. 1997;171:449–451
  18. Copeland JR, Dewey ME, Saunders P. The epidemiology of dementia: GMS-AGECAT studies of prevalence and incidence, including studies in progress. Eur Arch Psychiatry Clin Neurosci. 1991;240:212–217
  19. Grober E, Buschke H, Crystal H, Bang S, Dresner R. Screening for dementia by memory testing. Neurology. 1988;38:900–903
  20. Read DE. Neuropsychological assessment of memory in the elderly. Can J Psychol. 1987;41:158–174
  21. Brayne C, Calloway P. Normal ageing, impaired cognitive function, and senile dementia of the Alzheimer's type: a continuum?. Lancet. 1988;1:1265–1267
  22. Reischies FM, Schaub RT, Schlattmann P. Normal ageing, impaired cognitive functioning, and senile dementia—a mixture distribution analysis. Psychol Med. 1996;26:785–790
  23. Smith J, Baltes PB. Trends and profiles of psychological functioning in very old age. In: Baltes PB, Mayer KU editor. The Berlin Aging Study. New York, NY: Cambridge University Press; 1998;p. 197–226
  24. Katzman R. Education and the prevalence of dementia and Alzheimer's disease. Neurology. 1993;43:13–20
  25. Hörtnagl H, Hellweg R. Pathophysiological aspects of human neurodegenerative diseases. Wien Klin Wochenschr. 1997;109:623–635
  26. Convit A, De Leon MJ, Tarshish C, De Santi S, Tsui W, Rusinek H, et al. Specific hippocampal volume reductions in individuals at risk for Alzheimer's disease. Neurobiol Aging. 1997;18:131–138
  27. (Suppl) Dugan LL, Choi DW. Excitotoxicity, free radicals, and cell membrane changes. Ann Neurol. 1994;35:S17–S21
  28. Hellweg R, Jockers-Scherübl M. Neurotrophic factors in memory disorders. Life Sci. 1994;55:2165–2169
  29. Consensus Report of the Working Group on Molecular and Biochemical Markers of Alzheimer's Disease. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol Aging. 1998;19:109–116
  30. Bancher C, Jellinger K, Wichart I. Biological markers for the diagnosis of Alzheimer's disease. J Neural Transm Suppl. 1998;53:185–197
  31. Blennow K, Vanmechelen E. Combination of the different biological markers for increasing specificity of in vivo Alzheimer's testing. J Neural Transm Suppl. 1998;53:223–235
  32. Galasko D. Cerebrospinal fluid levels of Aβ42 and tau: potential markers of Alzheimer's disease. J Neural Transm Suppl. 1998;53:209–221
  33. Galasko D, Chang L, Morter R, Clark CM, Kaye J, Knopman D, et al. High cerebrospinal fluid tau and low amyloid β42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol. 1998;55:937–945
  34. Kanai M, Matsubara E, Isoe K, Urakami K, Nakashima K, Arai H, et al. Longitudinal study of cerebrospinal fluid levels of tau, Aβ1–40, and Aβ1–42(43) in Alzheimer's disease: a study in Japan. Ann Neurol. 1998;44:17–26
  35. Shoji M, Matsubara E, Kanai M, Watanabe M, Nakamura T, Tomidokoro Y, et al. Combination assay of CSF tau, Aβ1–40 and Aβ1–42(43) as a biochemical marker of Alzheimer's disease. J Neurol Sci. 1998;158:134–140
  36. Trojanowski JQ, Clark CM, Arai H, Lee V. Elevated levels of tau in cerebrospinal fluid: implications for the antemortem diagnosis of Alzheimer's disease. Alzheimer's Dis Rev. 1996;1:77–83
  37. Mecocci P, Chembini A, Bregnocchi M, Chionne F, Cecchetti R, Lowenthal DT, et al. Tau protein in cerebrospinal fluid: a new diagnostic and prognostic marker in Alzheimer disease?. Alzheimer Dis Assoc Disord. 1998;12:211–214
  38. Arai H, Nakagawa T, Kosaka Y, Higuchi S, Matsui T, Okamura N, et al. Elevated cerebrospinal fluid tau protein level as a predictor of dementia in memory-impaired individuals. Alzheimer's Res. 1997;3:211–213
  39. Riemenschneider M, Buch K, Schmolke M, Kurz A, Guder WG. Cerebrospinal protein tau is elevated in early Alzheimer's disease. Neurosci Lett. 1996;212:209–211
  40. Galasko D, Clark C, Chang L, Miller B, Green RC, Motter R, et al. Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease. Neurology. 1997;48:632–635
  41. Andreasen N, Vanmechelen E, Van de Voorde A, Davidsson P, Hesse C, Tarvonen S, et al. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study. J Neurol Neurosurg Psychiatry. 1998;64:298–305
  42. (Suppl) Arai H, Higuchi S, Sasaki H. Apolipoprotein E genotyping and cerebrospinal fluid tau protein: implications for the clinical diagnosis of Alzheimer's disease. Gerontology. 1997;43(1):2–10
  43. Tapiola T, Lehtovirta M, Ramberg J, Helisalmi S, Linnaranta K, Riekkinen P, et al. CSF tau is related to apolipoprotein E genotype in early Alzheimer's disease. Neurology. 1998;50:169–174
  44. Marz P, Heese K, Hock C, Golombowski S, Muller-Spahn F, Rose-John S, et al. Interleukin-6 (IL-6) and soluble forms of IL-6 receptors are not altered in cerebrospinal fluid of Alzheimer's disease patients. Neurosci Lett. 1997;239:29–32
  45. McRae A, Dahlstrom A, Polinsky R, Ling EA. Cerebrospinal fluid microglial antibodies: potential diagnostic markers for immune mechanisms in Alzheimer's disease. Behav Brain Res. 1993;57:225–234
  46. Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D, et al. Reduction of β-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol. 1995;38:643–648
  47. Southwick PC, Yamagata SK, Echols CL, Higson GJ, Neynaber SA, Parson RE, et al. Assessment of amyloid β protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease. J Neurochem. 1996;66:259–265
  48. Hock C, Golombowski S, Müller-Spahn F, Naser W, Beyreuther K, Monning U, et al. Cerebrospinal fluid levels of amyloid precursor protein and amyloid β-peptide in Alzheimer's disease and major depression-inverse correlation with dementia severity. Eur Neurol. 1998;39:111–118
  49. Tamaoka A, Fukushima T, Sawamura N, Ishikawa K, Oguni E, Komatsuzaki Y, et al. Amyloid β protein in plasma from patients with sporadic Alzheimer's disease. J Neurol Sci. 1996;141:65–68
  50. Beal M, Growdon JH. CSF neurotransmitter markers in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry. 1986;10:259–270
  51. Elble R, Giacobini E, Higgins C. Choline levels are increased in cerebrospinal fluid of Alzheimer patients. Neurobiol Aging. 1989;10:45–50
  52. van Gool WA, Bolhuis PA. Cerebrospinal fluid markers of Alzheimer's disease. J Am Geriatr Soc. 1991;39:1025–1039
  53. Jimenez-Jimenez FJ, Molina JA, Gomez P, Vargas C, de Bustos F, Benito-Leon J, et al. Neurotransmitter amino acids in cerebrospinal fluid of patients with Alzheimer's disease. J Neural Transm. 1998;105:269–277
  54. Hellweg R, von Richthofen S, Anders D, Baethge C, Röpke S, Hartung HD, et al. The time course of nerve growth factor content in different neuropsychiatric diseases-a unifying hypothesis. J Neural Transm. 1998;105:871–903
  55. Hellweg R, Baethge C, Hartung HD, Brückner MK, Arendt T. NGF level in the rat sciatic nerve is decreased after long-term consumption of ethanol. Neuroreport. 1996;7:777–780
  56. Hellweg R, Hartung HD. Endogenous levels of nerve growth factor (NGF) are altered in experimental diabetes mellitus: a possible role for NGF in the pathogenesis of diabetic neuropathy. J Neurosci Res. 1990;26:258–267
  57. Hellweg R, Raivich G, Hartung HD, Hock C, Kreutzberg GW. Axonal transport of endogenous nerve growth factor (NGF) and NGF receptor in experimental diabetic neuropathy. Exp Neurol. 1994;130:24–30
  58. Anand P, Terenghi G, Warner G, Kopelman P, Williams-Chestnut RE, Sinicropi DV. The role of endogenous nerve growth factor in human diabetic neuropathy. Nat Med. 1996;2:703–707
  59. Hellweg R, Gericke CA, Jendroska K, Hartung HD, Cervós-Navarro J. NGF content in the cerebral cortex of non-demented patients with amyloid-plaques and in symptomatic Alzheimer's disease. Int J Dev Neurosci. 1998;16:787–794
  60. Hellweg R. Trophic factors during normal brain aging and after functional damage. J Neural Transm Suppl. 1994;44:209–217
  61. Hörtnagl H, Hellweg R. Insights into the role of the cholinergic component of the septohippocampal pathway: what have we learned from experimental lesion studies?. Brain Res Bull. 1997;43:245–255
  62. Hellweg R, Fischer W, Hock C, Gage FH, Björklund A, Thoenen H. Nerve growth factor levels and choline acetyltransferase activity in the brain of aged rats with spatial memory impairments. Brain Res. 1990;537:123–130
  63. Hellweg R, Humpel C, Löwe A, Hörtnagl H. Moderate lesion of the rat cholinergic septohippocampal pathway increases hippocampal nerve growth factor synthesis: evidence for long-term compensatory changes?. Mol Brain Res. 1997;45:177–181
  64. Lorigados L, Soderstrom S, Ebendal T. Two-site enzyme immunoassay for β NGF applied to human patient sera. J Neurosci Res. 1992;32:329–339
  65. Murase K, Nabeshima T, Robitaille Y, Quirion R, Ogawa M, Hayashi K. NGF level is not decreased in the serum, brain-spinal fluid, hippocampus, or parietal cortex of individuals with Alzheimer's disease. Biochem Biophys Res Commun. 1993;28:198–203
  66. Dicou E, Vermersch P, Penission-Besnier I, Dubas F, Nerriere V. Anti-NGF autoantibodies and NGF in sera of Alzheimer patients and in normal subjects in relation to age. Autoimmunity. 1997;26:189–194
  67. Anders D. Nerve growth factor (NGF) im Humanserum-Die mögliche Bedeutung von NGF in der Psychiatric. In: Doctoral thesis. Berlin, Germany: Free University of Berlin; 1998;
  68. Lindner MD, Gordon DD, Miller JM, Tariot PN, McDaniel KD, Hamill RW, et al. Increased levels of truncated nerve growth factor receptor in urine of mildly demented patients with Alzheimer's disease. Arch Neurol. 1993;50:1054–1060
  69. Levi-Montalcini R, Skaper SD, Dal Toso R, Petrelli L, Leon A. Nerve growth factor: from neurotrophin to neurokine. Trends Neurosci. 1996;19:514–520

PII: S0010-440X(00)80011-5

Comprehensive Psychiatry
Volume 41, Issue 2, Supplement 1 , Pages 66-75 , March 2000

Article Tools